Drug Profile
Quisinostat - Janssen Pharmaceutica/NewVac
Alternative Names: JNJ-26481585Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Janssen Pharmaceutica; Janssen Research & Development; NewVac
- Class Antineoplastics; Hydroxy acids; Hydroxylamines; Piperidines; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Lung cancer; Ovarian cancer
- Preclinical Pulmonary arterial hypertension
- No development reported Breast cancer; Sarcoma
- Discontinued Cutaneous T-cell lymphoma; Leukaemia; Multiple myeloma; Myelodysplastic syndromes; Solid tumours
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Breast-cancer in Russia (PO)
- 28 Sep 2022 No recent reports of development identified for phase-I development in Sarcoma in Russia (PO)
- 08 Apr 2022 Pharmacodynamics data from a preclinical study in Glioblastoma presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)